文献速递药物不良反应与药物警戒

奥瑞珠单抗诱导性结肠炎:VigiBase 失衡分析、病例报告与文献综述

Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review.
PubMed 文献 · Br J Clin Pharmacol · 2026-02-15

该研究基于 VigiBase 对奥瑞珠单抗相关结肠炎进行失衡分析,并结合文献综述及卢森堡药警戒中心报告的 2 例病例。VigiBase 中检出 400 例结肠炎报告,79.0% 为严重病例,中位发病时间 17 个月,多个 PT 呈显著失衡;文献综述纳入 24 篇病例报告共 36 例患者,中位发病 18 个月,2 例在重新使用奥瑞珠单抗后复发。上述结果提示奥瑞珠单抗与结肠炎可能存在安全性信号。

要点

  • VigiBase 中奥瑞珠单抗相关结肠炎 400 例,79.0% 为严重病例,中位发病 17 个月。
  • 文献综述 24 篇病例报告共 36 例患者,中位发病 18 个月,非特指结肠炎占 61.1%。
  • 2 例患者在重新使用奥瑞珠单抗后复发,提示再暴露可能增加复发风险。

核心结论

  • 结合 VigiBase 显著失衡、文献病例及 2 例卢森堡病例,奥瑞珠单抗诱导性结肠炎存在潜在安全性信号。

研究设计与样本

  • 对 VigiBase 中奥瑞珠单抗诱导性结肠炎报告进行描述性与失衡分析,并开展广泛文献综述及报告 2 例卢森堡药警戒中心病例。

主要发现

  • VigiBase 分析检出 400 例奥瑞珠单抗诱导性结肠炎,79.0% 为严重病例,中位发病时间 17 个月。
  • VigiBase 中编码的首选术语为「结肠炎」占 53.0%,其次为炎症性肠病相关 PT 占 33.5%。
  • 高水平术语「结肠炎」及 PT「结肠炎」「显微镜下结肠炎」「免疫介导性小肠结肠炎」存在显著失衡。
  • 文献综述纳入 24 篇病例报告共 36 例患者,中位发病时间 18 个月,非特指结肠炎占 61.1%,炎症性肠病占 27.8%。
  • 2 例患者在重新使用奥瑞珠单抗后复发。

临床怎么用

  • 临床使用奥瑞珠单抗期间应警惕结肠炎,尤其关注严重病例及延迟发病(中位 17–18 个月)的可能。
  • 对疑似奥瑞珠单抗诱导性结肠炎患者,再次使用奥瑞珠单抗前应评估复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ocrelizumab is a humanized anti-CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab-induced colitis have been reported in the scientific literature. METHODS: To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and disproportionality analysis of ocrelizumab-induced colitis registered in VigiBase, as well as an extensive literature review and a description of two cases from Luxembourg reported to our pharmacovigilance centre. RESULTS: Our VigiBase analysis revealed 400 cases of ocrelizumab-induced colitis, with 79.0% serious cases and a median time to onset of 17 months. The preferred term (PT) coded was 'colitis' (53.0%), followed by PTs related to inflammatory bowel diseases (33.5%). Significant disproportionality was found for high-level term 'colitis' and for 'colitis', 'colitis microscopic' and 'immune-mediated enterocolitis' PTs. Our literature review revealed 24 case reports corresponding to 36 patients with a median time to onset of 18 months and a predominance of unspecified colitis (61.1%) and inflammatory bowel diseases (27.8%). Two patients relapsed after ocrelizumab resumption. CONCLUSIONS: Together, our findings of two relevant clinical cases of ocrelizumab-induced colitis, the literature review and the significant VigiBase disproportionality, suggest a potential safety signal for ocrelizumab.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Fresse A, Hommel C, Petitpain N, et al. Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review. Br J Clin Pharmacol. 2026. PMID: 41693080. doi:10.1002/bcp.70490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。